Derek Chaves Appointed Chief Financial Officer of Corza Medical

Udgivet den 11-07-2024  |  kl. 11:55  |  

WESTWOOD, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Corza Medical ("Corza" or the "Company") is proud to announce the appointment of Derek Chaves as its new Chief Financial Officer (CFO), effective July 8, 2024. Corza Medical, a rapidly growing global leader in medical technology and innovative surgical solutions, is recognized for its comprehensive approach to excellence in customer service and partnerships. Derek's appointment underscores Corza's commitment to scaling operations and driving further growth in a complex and dynamic market landscape.

Derek brings over 25 years of broad experience in finance and accounting within the medical technologies and life sciences sectors, including roles of increasing responsibility at C.R. Bard, later acquired by Becton Dickinson. Most recently, Derek served as Vice President, Finance for the $3.6B Integrated Diagnostic Solutions global business unit at Becton Dickinson and previously held the role of VP, Finance for Becton Dickinson's global Surgery business unit.

"Derek's appointment comes at a pivotal time for Corza Medical as we have surpassed the half-billion revenue threshold and continue to innovate and expand our capabilities," said Gregory T. Lucier, Corza Medical Executive Chairman. "His global experience in finance, understanding of the complexities of our industry, and his proven track record supporting rapid growth while ensuring operational efficiencies will be instrumental in our future success."

"Derek's deep expertise across medical device and pharmaceutical operations uniquely qualifies him to drive value creation as we expand our global footprint and enhance our offerings. He is an invaluable addition to our executive team," added Tom Testa, Corza Medical's Chief Executive Officer.

Derek holds a Bachelor of Science in Business Administration from Bryant University and a Master of Business Administration from Charleston Southern University. His comprehensive background and leadership skills will play a crucial role in Corza Medical's ongoing success and mission to deliver cutting-edge solutions to healthcare professionals worldwide through remarkable service, trusted performance, and outstanding value.

About Corza Medical  
Corza Medical is a leading global manufacturer of innovative surgical technologies. With a global team of over 3,000 employees supporting clinicians, distributor-partners, and medical device companies worldwide, Corza provides healthcare professionals a platform of surgical technologies with many industry-leading brands, including Quill® barbed sutures, Sharpoint® Plus and Look™ surgical sutures, Katena® reusable and Blink™ single-use ophthalmic instruments, Barron corneal transplant devices, Sharpoint® microsurgical knives, and the TachoSil® fibrin sealant patch. For more information, please visit www.corza.com.


\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

17:56 Europa/lukning: Siemens Energy endte i rekord efter AI-løfte fra Trump
17:08 Onsdagens aktier: Ørsted fortsatte nedturen i let rødt C25
17:06 Onsdagens obligationer: Renten endte fladt på trods af ECB-taler
16:22 Ny tiårig statsobligation bliver den toneangivende til februar
16:11 Italiensk NKT-konkurrent i rekord på aflyst ameikansk fabriksprojekt
16:00 Goldman om Ørsted: Nyt tilbageslag kan være på vej
15:51 USA/åbning: Netflix fører an i bred tech-optur
15:42 Amerikansk forbrugsvaregigant i hopla på ødsle forbrugere
14:38 USA/tendens: Netflix tager fokus med vild kundehøst i ventet grøn åbning
14:08 Vestas og Ørsted er blandt seks danske selskaber på bæredygtig liste
13:29 Europa/aktier: Indeks på rekordkurs med svensk AI-selskab i top
13:17 Siemens Energy er flyvende på undervurderede muligheder inden for gasdrevne AI-datacentre
12:32 Genmab-partners salg af guldæg lever op til seneste prognose
12:16 Vestas får milliardordre i Ukraine
11:39 Obligationer/middag: Renten bevæger sig sidelæns før Lagarde går på talerstolen i Davos
11:38 Aktier/middag: Novo tager fronten i grønt C25 mens Ørsted fortsætter nedtur
10:28 ECB's Lagarde afviser at være bagud med rentenedsættelserne
10:23 DFDS-topchef: Kapacitet i Middelhavet skal tilpasses - ser nettooverskud nær breakeven i 2025
09:30 H+H er ifølge Danske Bank en opkøbskandidat: Hæver anbefaling til "køb"
09:27 Aktier/åbning: Grøn åbning med Novo Nordisk i top - DFDS i stiv kuling efter melding